The incidence and complications arising from airway diseases are constantly increasing and chronic conditions of the airway significantly outnumber those of diabetes, cancer, heart disease combined. A quarter of the U.S. population are affected by airway diseases such as acute and chronic bronchitis, pneumonia, cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, bronchiolitis, ventilator-associated airway mucus hyper-secretion, and acute and chronic sinusitis. Mucus overproduction and hypersecretion have been implicated to play a key role in these airway diseases. However, mucus pathology is very poorly understood and hence recent advances have not been sufficient to develop effective treatments. Existing mucolytic drugs provide only moderate relief and have a number of limitations such as weak potency, volatility, bad smell in addition to side effects such as nausea, rash and sores. There is a need to address the large unmet need for novel mucolytic therapies for a wide range of acute and chronic airway disease.